Cardiovascular

[Across-sectional study on the association between steatotic liver disease and its subtypes, cardiovascular health status, and extrahepatic comorbidity].

TL;DR

Cardiovascular-renal-metabolic diseases impose a substantial burden on patients with steatotic liver disease, metabolic disorders are more pronounced among ALD patients, and the LE8 score is significantly negatively correlated with T2DM and HTN prevalence in SLD patients.

Key Findings

The prevalence of SLD and its subtypes MASLD, MetALD, and ALD were 42.15%, 39.00%, 1.48%, and 1.57%, respectively, among 9,779 subjects aged 40–70 years.

  • Total study population: 9,779 subjects from the Shanghai Chongming Town Community Residents Cohort (March–November 2011).
  • SLD prevalence: 4,122/9,779 (42.15%); MASLD: 3,814/9,779 (39.00%); MetALD: 145/9,779 (1.48%); ALD: 154/9,779 (1.57%).
  • SLD was classified using sonographic diagnosis and categorized by metabolic cardiovascular risk factors and alcohol consumption.
  • MASLD was by far the most common subtype, accounting for the vast majority of SLD cases.

Prevalence rates of T2DM, HTN, CKD, and CVD were significantly higher in SLD patients compared to non-SLD patients.

  • All four comorbidities (T2DM, HTN, CKD, CVD) showed significantly higher prevalence in the SLD group versus non-SLD group (P<0.05).
  • SLD patients showed significant metabolic disturbance characteristics compared to the non-SLD population.
  • The cross-sectional design was based on baseline data from a Chinese T2DM patient subcohort.

Prevalence rates of T2DM, HTN, CKD, and CVD were significantly higher in the high-risk liver fibrosis group (FIB-4 >2.67) than in the non-high-risk group.

  • FIB-4 index threshold of >2.67 was used to define the high-risk liver fibrosis group.
  • All four conditions (T2DM, HTN, CKD, CVD) were significantly more prevalent in the high-risk FIB-4 group (P<0.05).
  • FIB-4 is a non-invasive liver fibrosis index used as a surrogate marker for advanced hepatic fibrosis.

MetALD and ALD patients had higher prevalence rates of hypertension than MASLD patients.

  • HTN prevalence was significantly higher in MetALD and ALD groups compared to MASLD (P<0.05).
  • All ALD patients had combined metabolic cardiovascular risk factors.
  • The prevalence rates of MetS, T2DM, HTN, and CVD showed an increasing trend from MASLD to MetALD to ALD.

No significant differences in the history of extrahepatic malignancies were observed between SLD and non-SLD groups or among SLD subgroups.

  • Extrahepatic malignancy history did not differ significantly between SLD and non-SLD groups.
  • No significant differences in extrahepatic malignancies were found among SLD subtypes (MASLD, MetALD, ALD).
  • The study was conducted within a subcohort of the Malignancy Occurrence Risk Epidemiology Study, specifically designed to assess cancer risk.

The LE8 (Life's Essential 8) score was significantly negatively correlated with T2DM and HTN prevalence in the overall population, with protective effects validated in non-SLD, SLD, and MASLD subgroups.

  • Multivariate logistic regression analysis confirmed LE8 score was significantly negatively correlated with T2DM and HTN prevalence rates (P<0.05).
  • The protective association of higher LE8 scores held in non-SLD patients, SLD patients, and MASLD patients specifically (all P<0.05).
  • LE8 score assesses cardiovascular health status across multiple dimensions including behavioral and biological health factors.
  • The analysis did not find statistically significant LE8 associations for MetALD or ALD subgroups specifically.

The development of extrahepatic comorbidities in MetALD and ALD patients is jointly driven by overnutrition and harmful alcohol consumption.

  • MetALD is defined as metabolic and alcohol-associated fatty liver disease, combining both metabolic risk factors and alcohol use.
  • ALD patients all had combined metabolic cardiovascular risk factors in this cohort.
  • The authors conclude that both overnutrition and harmful alcohol consumption jointly drive extrahepatic comorbidity development in MetALD and ALD.

What This Means

This research studied the relationship between fatty liver disease (called steatotic liver disease or SLD) and other serious health conditions in nearly 10,000 Chinese adults aged 40–70 years from Shanghai. The study found that about 42% of participants had SLD, with the most common type being metabolic-associated fatty liver disease (MASLD, ~39%), while alcohol-related forms were less common (about 1.5% each). People with SLD had significantly higher rates of type 2 diabetes, high blood pressure, chronic kidney disease, and cardiovascular disease compared to those without SLD. Furthermore, patients with more advanced liver scarring (measured by a blood test called FIB-4) also had higher rates of all these conditions. Notably, no link was found between SLD and a history of cancers outside the liver. The study also found that different subtypes of SLD carry different risks: people with alcohol-related liver disease (ALD) and combined metabolic-alcohol liver disease (MetALD) had higher rates of high blood pressure than those with purely metabolic fatty liver disease. ALD patients showed the highest burden of metabolic disorders, and the rates of diabetes, high blood pressure, metabolic syndrome, and cardiovascular disease all increased progressively from MASLD to MetALD to ALD. This suggests that alcohol use, on top of metabolic risk factors, substantially worsens the overall health burden. This research suggests that a cardiovascular health scoring tool called LE8 (Life's Essential 8), which measures multiple health behaviors and biological factors, may be useful for identifying and managing diabetes and high blood pressure risk in people with SLD. Higher LE8 scores were associated with lower rates of diabetes and high blood pressure across the overall population and specifically in people with MASLD. This points to the potential value of comprehensive cardiovascular health assessments for guiding preventive strategies in fatty liver disease patients, particularly targeting diabetes and hypertension.

Have a question about this study?

Citation

Guan J, Yang R, Yan J, Shi Y, He X, Qin L, et al.. (2026). [Across-sectional study on the association between steatotic liver disease and its subtypes, cardiovascular health status, and extrahepatic comorbidity].. Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology. https://doi.org/10.3760/cma.j.cn501113-20260609-00241